Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?

AIDS and Behavior

Volumn 20, Issue 11, 2016, Pages 2654-2661

  Mensch, Barbara S ^a   Brown, Elizabeth R ^b,c   Liu, Karen ^c   Marrazzo, Jeanne ^b   Chirenje, Zvavahera Mike ^d   Gomez, Kailazarid ^e   Piper, Jeanna ^f   Patterson, Karen ^c   van der Straten, Ariane ^g  

^a POPULATION COUNCIL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UZ UCSF Collaborative Research Programme   (Zimbabwe)

^e FHI 360   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g RTI INTERNATIONAL   (United States)

Author keywords

Microbicide trials; Self reports of adherence; sub Saharan Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR;

ADULT; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DECEPTION; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRE-EXPOSURE PROPHYLAXIS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SELF DISCLOSURE; SOUTH AFRICA; UGANDA; YOUNG ADULT; ZIMBABWE;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; DECEPTION; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; FEMALE; GELS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; SELF DISCLOSURE; SOUTH AFRICA; TENOFOVIR; UGANDA; YOUNG ADULT; ZIMBABWE;

EID: 84959095478     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-016-1312-2     Document Type: Article

References (22)

1. Coly A, Gorbach PM. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS. 2008;3(5):581–6.
2. Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP Trials: current status and a reconceptualization. Curr Opin HIV AIDS. 2012;7(6):534–41.
3. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.
4. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
5. Trussell J, Dominik R. Will microbicide trials yield unbiased estimates of microbicide efficacy? Contraception. 2005;72(6):408–13.
6. Masse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5.
7. Rees H, Delany-Moretlwe S, Baron D, et al. FACTS 001 phase III trial of pericoital tenofovir 1 % gel for HIV prevention in women. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015. p. 23–26
8. Gorbach P, Mensch BS, Husnik M, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2013;17(2):790–800.
9. Mensch BS, Hewett PC, Abbott S, et al. Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav. 2011;15(2):407–21.
10. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
11. Abbott SA, Friedland BA, Sarna A, et al. An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India. AIDS Behav. 2013;17(6):2222–36.
12. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2012;10(1):89–102.
13. Servick K. ‘Nonadherence’: a bitter pill for drug trials. Science. 2014;346(6207):288–9.
14. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.
15. Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.
16. van der Straten A, Mayo A, Brown ER, et al. Perceptions and experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 trial. AIDS Behav. 2015;19(5):770–83.
17. Musara P, Munaiwa O, Mahaka I, et al. The effect of presentation of pharmacokinetic (PK) drug results on self-reported study product adherence among VOICE participants in Zimbabwe. HIV Research for Prevention Conference, Cape Town; 2014.
18. Corneli AL, McKenna K, Perry B, et al. The science of being a study participant: FEM-PrEP participants’ explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015;68(5):578–84.
19. van der Straten A, Montgomery ET, Musara P, et al. Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015;29(16):2161–71.
20. Minnis AM, van der Straten A, Salee P, Hendrix CW. Pre-exposure prophylaxis adherence measured by plasma drug level in MTN-001: comparison between vaginal gel and oral tablets in two geographic regions. AIDS Behav. 2015;. doi:10.1007/s10461-015-1081-3.
21. van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(Suppl 2):19146.
22. van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.